ImmunoGen shares are trading higher after the company presented updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab in patients with frontline and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.
Portfolio Pulse from Benzinga Newsdesk
ImmunoGen shares are trading higher after the company presented updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab in patients with frontline and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.
June 09, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunoGen shares are trading higher after positive interim analysis of the Phase 2 CADENZA trial of pivekimab.
The positive interim analysis of the Phase 2 CADENZA trial of pivekimab indicates that the drug is showing promising results in treating patients with blastic plasmacytoid dendritic cell neoplasm. This news is likely to boost investor confidence in ImmunoGen, leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100